Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor.
- 1 August 1991
- journal article
- abstracts
- Published by Wolters Kluwer Health in Circulation
- Vol. 84 (2) , 821-827
- https://doi.org/10.1161/01.cir.84.2.821
Abstract
BACKGROUND This study was designed to determine whether arterial reocclusion after thrombolysis can be prevented by lipoprotein-associated coagulation inhibitor (LACI), a physiological inhibitor of tissue factor-induced coagulation mediated by the extrinsic pathway. METHODS AND RESULTS Thrombosis was induced in femoral arteries of anesthetized dogs with the use of anodal current to elicit extensive vascular injury and formation of platelet-rich thrombi in one artery and with thrombogenic copper wire to elicit fibrin-rich thrombi without appreciable vascular injury in the contralateral artery. Recanalization of both vessels was induced with t-PA (1.7 mg/kg i.v. over 1 hour) and verified with Doppler flow probes. Reocclusion occurred within 2 hours in seven of seven arteries with electrical injury-induced thrombosis and in four of seven arteries with copper wire-induced thrombosis in the absence of LACI. In dogs given infusions of recombinant DNA-produced LACI (225 micrograms/kg over 15 minutes, followed by 4 micrograms/kg/min i.v.) after completion of the infusion of t-PA, no reocclusion occurred during the 2-hour interval of observation in any of the five arteries subjected to electrical injury (p less than 0.001), and cyclic partial occlusions were nearly abolished (0.4 +/- 0.4/hr in LACI-treated dogs compared with 13.7 +/- 5.5/hr in saline-treated dogs, p less than 0.0001). In contrast, reocclusion occurred in two of five arteries with indwelling copper wires, and cyclic partial occlusions were unaffected despite LACI. LACI prolonged the partial thromboplastin time modestly (1.7 +/- 0.2 x baseline) but did not affect platelet counts or aggregation assessed ex vivo. CONCLUSIONS Inhibition of the extrinsic pathway of coagulation with LACI prevents thrombotic arterial reocclusion after thrombolysis in vessels subjected to extensive vascular injury. Our results demonstrate that activation of the extrinsic pathway plays a critical role in thrombotic reocclusion and that LACI provides a highly targeted approach to facilitate sustained recanalization without directly inhibiting platelets.Keywords
This publication has 24 references indexed in Scilit:
- A Comparison between Heparin and Low-Dose Aspirin as Adjunctive Therapy with Tissue Plasminogen Activator for Acute Myocardial InfarctionNew England Journal of Medicine, 1990
- Platelet aggregation and interaction with the coagulation systemCoronary Artery Disease, 1990
- Mechanism of action of heparin and anticoagulant therapyCoronary Artery Disease, 1990
- Platelets and Thrombolytic TherapyNew England Journal of Medicine, 1990
- After coronary thrombolysis and reperfusion, What next?Journal of the American College of Cardiology, 1989
- Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarctionJournal of the American College of Cardiology, 1989
- Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury.Journal of Clinical Investigation, 1989
- Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA)Thrombosis Research, 1988
- Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysisJournal of the American College of Cardiology, 1986
- Tissue Factor (Thromboplastin): Localization to Plasma Membranes by Peroxidase-Conjugated AntibodiesScience, 1972